Coronavirus disease 2019 in Latin American patients with multiple sclerosis

Yara D. Fragoso, Irene Schiavetti, Luca Carmisciano, Marta Ponzano, Judith Steinberg, Irene Treviño-Frenk, Ethel Ciampi, Maria Cecilia A. Vecino, Edgar P. Correa, Claudia Carcamo, Sidney Gomes, Maria Lucia V. Pimentel, Gutemberg A.C. Santos, Carlos Vrech, Thereza C.A. Winckler, Maria Pia Sormani

Research output: Contribution to journalLetterpeer-review


Patients with multiple sclerosis (MS) who present coronavirus disease 2019 (COVID-19) are of particular interest to neurologists. These patients have a neuroimmune disease and receive immunomodulatory or immunosuppressive therapies in the long-term. We present here data from 73 patients with MS and a confirmed diagnosis of COVID-19 from five Latin American countries. Fifteen patients (20.5%) were hospitalized and two patients died. The use of anti-CD20 therapies was the only risk factor associated to hospitalization and death. Despite the small sample size, this study highlights the awareness regarding therapeutic options for MS during the pandemic.

Original languageEnglish
Article number103173
JournalMultiple Sclerosis and Related Disorders
Publication statusPublished - Oct 2021


  • COVID-19
  • Multiple sclerosis
  • ocrelizumab
  • Pandemic
  • rituximab

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Coronavirus disease 2019 in Latin American patients with multiple sclerosis'. Together they form a unique fingerprint.

Cite this